Novartis psoriasis drug bests Enbrel in trial

|By:, SA News Editor

Novartis' (NVS +0.1%) IL-17A inhibitor secukinumab cleared skin faster and for longer than Enbrel (AMGN -0.9%) in a Phase 3 plaque psoriasis study.

FIXTURE met all primary and secondary endpoints.

Here's NVS' head of pharmaceuticals with the no-frills take: "These exciting data suggest that with secukinumab, we have the potential to help more patients achieve clear skin, which is the ultimate treatment goal."

Expect regulatory submissions later this year in both the U.S. and Europe. (PR)